Business / Finance

RSS

Viropharma announces financial results for second quarter of 2013

VIROPHARMA INCORPORATED (Nasdaq: VPHM) today announced financial results for the second quarter of 2013. Net sales were $104 million for the second quarter ended June 30, 2013 as compared to $95 million in the comparative period of 2012.

1 Aug 2013

BD reports quarterly revenues of $2.053 billion for third fiscal quarter

BD (Becton, Dickinson and Company), a leading global medical technology company, today reported quarterly revenues of $2.053 billion for the third fiscal quarter ended June 30, 2013, representing an increase of 3.6 percent from the prior-year period, or 5.1 percent on a foreign currency-neutral basis.

From BD (Becton, Dickinson and Company) 1 Aug 2013

Nu Skin Enterprises Q2 revenue increases 15% to $682.9 million

Nu Skin Enterprises, Inc. today announced record second-quarter results with revenue of $682.9 million, a 15 percent increase over the prior-year period. Revenue for the quarter was negatively impacted 3 percent by foreign currency fluctuations. Quarterly earnings per share increased 30 percent to $1.22 from $0.94 in the prior year.

1 Aug 2013

Sequenom CMM, CombiMatrix sign collaboration agreement to market CMA testing for NIPT

Sequenom, Inc., a life sciences company providing innovative diagnostic testing and genetic analysis solutions, and CombiMatrix Corporation, a molecular diagnostics laboratory performing DNA-based testing services for developmental disorders and cancer, today jointly announced that the Sequenom Center for Molecular Medicine LLC and CombiMatrix have entered into a collaboration agreement to market chromosomal microarray analysis testing services to broaden and confirm the results of noninvasive, prenatal testing to physicians and their patients.

1 Aug 2013

Rheonix, Life Technologies sign joint development agreement for molecular testing platform

Rheonix, Inc., a developer of fully automated molecular testing solutions, and Life Technologies Corp., a global leader in the life sciences tools and diagnostic markets, have entered into a joint development agreement to introduce a molecular testing platform for their Applied Markets business.

1 Aug 2013

Mastech Holdings enters into definitive asset purchase agreement with Accountable Healthcare Staffing

Mastech Holdings, Inc., a national provider of Information Technology and Specialized Healthcare staffing services, announced today that it has entered into a definitive asset purchase agreement with Accountable Healthcare Staffing, Inc. to sell substantially all of the assets of its Healthcare Staffing segment.

31 Jul 2013

MiMedx Group Q2 revenue increases more than 175%

MiMedx Group, Inc., an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its results for the quarter ended June 30, 2013.

31 Jul 2013

Triple-S Management reports consolidated revenues of $599.8 million for Q2 2013

Triple-S Management Corporation, the leading managed care company in Puerto Rico, today announced consolidated revenues of $599.8 million and consolidated operating income of $16.8 million for the three months ended June 30, 2013.

31 Jul 2013

Blackbaud announces total revenue increase of 14% for Q2 2013

Blackbaud, Inc., a leading global provider of software and services for nonprofits, today announced financial results for its second quarter ended June 30, 2013.

31 Jul 2013

Naurex receives new U.S. patent for its lead compound, GLYX-13

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced issuance of a new U.S. patent for its lead compound, GLYX-13.

31 Jul 2013

Hamamatsu places $500,000 order for Zecotek’s LFS scintillation crystals

Zecotek Photonics Inc., a developer of leading-edge photonics technologies for medical, industrial and scientific markets, today announced that it has received a $500,000 order for its patented Lutetium Fine Silicate (LFS) scintillation crystals from its strategic partner Hamamatsu Photonics (Tokyo: 6965) of Japan.

31 Jul 2013

Baxter, JW Holdings sign distribution, license agreement for omega 3 parenteral nutrition products

Baxter International Inc. and JW Holdings today announced that they have entered into an exclusive distribution and license agreement for parenteral nutritional products containing a novel formulation of omega 3 lipids.

From Baxter International Inc. 31 Jul 2013

AstraZeneca, FibroGen partner to develop, commercialize anemia drug candidate FG-4592

AstraZeneca and FibroGen today announced that they have entered into a strategic collaboration to develop and commercialize FG-4592, a first-in-class oral compound in late stage development for the treatment of anemia associated with chronic kidney disease and end-stage renal disease.

31 Jul 2013

Community Health Systems, Health Management Associates enter into definitive merger agreement

Community Health Systems, Inc. and Health Management Associates, Inc. announced today that they have entered into a definitive merger agreement pursuant to which CHS will acquire HMA for approximately $7.6 billion, including the assumption of approximately $3.7 billion of indebtedness.

30 Jul 2013

Adocia, Lilly terminate collaboration agreement relating to fast-acting insulin analog

Adocia, a biotechnology company specializing in the development of ‘best-in-class’ medicines from already approved therapeutic proteins, announced today that it had agreed with Eli Lilly and Company not to continue further joint research under the licensing agreement signed in December 2011 relating to use of Adocia's BioChaperone(R) technology for the formulation of fast acting insulin analog formulated with the BioChaperone(R) technology. Consequently, the two companies have terminated the collaboration.

30 Jul 2013

National health and social care charity, Community Integrated Care, launches new five year strategy

National health and social care charity Community Integrated Care is proud to announce the launch of its new five year strategy, in which the organisation has committed to becoming ‘The UK’s Leading Health and Social Care Charity’.

From Community Integrated Care 29 Jul 2013

FDA grants orphan-drug designation for Ligand’s Captisol-enabled Topiramate Injection

Ligand Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation for its proprietary Captisol-enabled Topiramate Injection for the treatment of partial onset or primary generalized tonic-clonic seizures in hospitalized epilepsy patients who are unable to take oral topiramate.

26 Jul 2013

Columbia Laboratories’ Board of Directors set a ratio of 1-for-8 for its reverse stock split

Columbia Laboratories, Inc. ("Columbia" or the "Company") (NasdaqCM: CBRX) announced today that its Board of Directors (the "Board") has set a ratio of 1-for-8 for its previously approved reverse stock split of its common stock, and an anticipated effective date for the reverse stock split of the later of (i) the filing with the Secretary of the State of Delaware of a certificate of amendment with respect to the reverse stock split or (ii) August 9, 2013.

26 Jul 2013

Piramal's Healthcare invests USD 2.5 million to upgrade ADC manufacturing suites

Piramal's Healthcare vertical today announced that it is to invest USD 2.5 million at its FDA approved Grangemouth, UK, site to upgrade one of its antibody drug conjugate (ADC) manufacturing suites, from clinical phase to commercial grade, in response to customer demand.

26 Jul 2013

Zydus, IDRI partner to develop visceral leishmaniasis vaccine candidate

In a unique partnership, Zydus, India's fourth largest healthcare group and an innovation-led global healthcare provider, and IDRI, a Seattle-based non-profit research and product development organization, announced today they are collaborating on the production and clinical development of IDRI's visceral leishmaniasis vaccine candidate, designed to prevent the deadly parasitic disease.

26 Jul 2013

Business / Finance

Viropharma announces financial results for second quarter of 2013

BD reports quarterly revenues of $2.053 billion for third fiscal quarter

Nu Skin Enterprises Q2 revenue increases 15% to $682.9 million

Sequenom CMM, CombiMatrix sign collaboration agreement to market CMA testing for NIPT

Rheonix, Life Technologies sign joint development agreement for molecular testing platform

Mastech Holdings enters into definitive asset purchase agreement with Accountable Healthcare Staffing

MiMedx Group Q2 revenue increases more than 175%

Triple-S Management reports consolidated revenues of $599.8 million for Q2 2013

Blackbaud announces total revenue increase of 14% for Q2 2013

Naurex receives new U.S. patent for its lead compound, GLYX-13

Hamamatsu places $500,000 order for Zecotek’s LFS scintillation crystals

Baxter, JW Holdings sign distribution, license agreement for omega 3 parenteral nutrition products

AstraZeneca, FibroGen partner to develop, commercialize anemia drug candidate FG-4592

Community Health Systems, Health Management Associates enter into definitive merger agreement

Adocia, Lilly terminate collaboration agreement relating to fast-acting insulin analog

National health and social care charity, Community Integrated Care, launches new five year strategy

FDA grants orphan-drug designation for Ligand’s Captisol-enabled Topiramate Injection

Columbia Laboratories’ Board of Directors set a ratio of 1-for-8 for its reverse stock split

Piramal's Healthcare invests USD 2.5 million to upgrade ADC manufacturing suites

Zydus, IDRI partner to develop visceral leishmaniasis vaccine candidate

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Latest News